Affimed Gmbh

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Affimed Therapeutics, Ag

Sergey Kipriyanov

Melvyn Little

Uwe Reusch

Fabrice Le Gall

Stefan Knackmuss

Karin Hoffmann

Frank Breitling

Peter Röttgen

Stefan Dubel

Vera Mick

Hans-Jurgen Rode

Stefanie Gotter

Schirrmacher Volker

Khashayarsha Khazaie

Claudia Haas

Gerd Moldenhauer

Melvin Little

Stefan Weiss

The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc&#x3b3;RIIIA), and in particular binding molecules that specifically bind the A form Fc&#x3b3;RIII but do not bind to the B form of Fc&#x3b3;RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.

Anti-CD16 binding molecules

Described are mono- and multivalent scFv-antibodies comprising the binding sites specific for the human T cell marker CD3. These antibodies are strongly immunosuppressive and do not cause a significant release of cytokines. Furthermore, polynucleotides encoding said antibodies are described as well as vectors comprising said polynucleotides, host cells transformed therewith and their use in the production of said antibodies. Pharmaceutical compositions containing any of the above mentioned polynucleotides, antibodies or vectors are useful for immunotherapy, preferably against acute transplant rejections.

Human CD3-specific antibody with immunosuppressive properties

Described is the use of a recombinant antibody comprising a binding site specific for an epitope of the laminin receptor or laminin receptor precursor for the treatment or diagnosis of various cancers, particularly B-CLL. Preferably, this antibody additionally comprises a binding site for at least one particular cell surface antigen.

Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment or diagnosis of several cancer types

Cell surface protein and effector cell bonding reagent

Growing community of inventors

Heidelberg, Germany

Sergey Kipriyanov